Synta Pharmaceuticals Corp. (SNTA) announced financial results for the 4th Q and year ended December 31, 2013 and provided an update on recent corporate events. Keith Gollust, Chairman of the Executive Committee of the company stated that the team at Synta has made important progress with its two lead programs, ganetespib and the HDC platformas well as the ongoing progress of the pivotal GALAXY-2 trial, SNTA has supported a growing pipeline of randomized studies with ganetespib, including investigator-sponsored trials in breast cancer, ovarian cancer, AML and high risk MDS. Synta Pharmaceuticals Corp.(NASDAQ:SNTA) shares after opening at $4.39 moved to $4.76 on last trade day and at the end of the day closed at $4.71. Company price to cash ratio in past twelve months was calculated as 3.96. Synta Pharmaceuticals Corp.(NASDAQ:SNTA) showed a negative weekly performance of -10.80%.
XOMA Corp (NASDAQ:XOMA) CEO John Varian unloaded 10,000 shares of the company’s stock in a transaction dated Monday, March 17th. The shares were sold at an average price of $6.03, for a total value of $60,300.00. Following the sale, the chief executive officer now directly owns 270,035 shares of the company’s stock, valued at approximately $1,628,311. XOMA Corp (NASDAQ:XOMA) shares advance 7.56% in last trading session and ended the day on $6.40. XOMA return on assets is -152.10%. XOMA Corp (NASDAQ:XOMA) yearly performance is 93.35%.
Investors in Idenix Pharmaceuticals Inc (NASDAQ:IDIX) saw new options begin trading this week, for the October 18th expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 214 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration. At Stock Options Channel , our YieldBoost formula has looked up and down the IDIX options chain for the new October 18th contracts and identified one put and one call contract of particular interest. Idenix Pharmaceuticals Inc (NASDAQ:IDIX) shares moved up 8.46% in last trading session and was closed at $7.82, while trading in range of $7.21 – 8.11 . Idenix Pharmaceuticals Inc year to date (YTD) performance is 30.77%.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) shares are showing positive movement yesterdat after the biopharmaceutical company posted narrower-than-expected loss for the fourth quarter. Progenics reported a loss of 14 cents per share for the quarter, versus a loss of 19 cents per share estimated by analysts. PGNX has a market capitalization of $329.72 million. Progenics Pharmaceuticals, Inc.(NASDAQ:PGNX) weekly performance is 0.59%. On last trading day company shares ended up $4.74 .Progenics Pharmaceuticals, Inc.(NASDAQ:PGNX) distance from 50-day simple moving average (SMA50) is -10.21%. Analysts mean target price for the company is $9.50.
Leave a Reply